Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis - PubMed (original) (raw)

Clinical Trial

Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis

Nimer Assy et al. Gut. 2007 Mar.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Bugianesi E, Leone N, Vanni E.et al Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002123134–140. - PubMed
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 20023461221–1231. - PubMed
    1. Kushner R F. Medical management of obesity. Semin Gastrointest Dis 200213123–132. - PubMed
    1. Davidson M H, Hauptman J, DiGirolamo M.et al Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999281235–242. - PubMed
    1. Zavoral J H. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998162013–2017. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources